Bolognesi M, Sacerdoti D, Merkel C, Gatta A
Centro di Spleno-Epatologia, University of Padua, Italy.
J Ultrasound Med. 1994 Dec;13(12):945-52. doi: 10.7863/jum.1994.13.12.945.
Thirty-eight cirrhotic patients with esophageal varices were investigated by duplex Doppler sonography. In every patient, the portal blood flow mean velocity (cm/sec) and portal blood flow volume (ml/min) were measured. In addition, the pulsatility index [(maximum-minimum)/mean velocity] was measured in the superior mesenteric artery, in the hepatic arteries, in an intrasplenic artery, and in intrarenal arteries. These parameters were measured again 120 to 180 minutes after administration of nadolol (80 mg orally) in 22 patients, 90 minutes after administration of isosorbide-5-mononitrate (20 mg orally) in nine patients, and subsequently after administration of isosorbide 5-mononitrate to 10 of the 22 patients treated earlier with nadolol. Duplex Doppler sonographic parameters also were evaluated in seven patients 120 minutes after administration of a placebo. In five of the 22 patients treated acutely with nadolol, the same parameters were measured again after 60 minutes without any additional drug administration. No hemodynamic changes occurred in response to the placebo. Portal blood flow mean velocity and portal blood flow volume decreased after nadolol and isosorbide-5-mononitrate; mesenteric pulsatility index increased after both nadolol and isosorbide-5-mononitrate. After combined therapy, we observed a further reduction in portal blood flow mean velocity and portal blood flow volume and a significant increase in hepatic, splenic, and mesenteric pulsatility indices. The addition of isosorbide-5-mononitrate to nadolol caused a decrease in portal blood flow mean velocity of more than 17% in all patients. Nadolol caused a slight increase in renal pulsatility index, which was amplified by the addition of isosorbide-5-mononitrate, suggesting a decrease in renal blood flow.
对38例患有食管静脉曲张的肝硬化患者进行了双功多普勒超声检查。对每位患者测量门静脉血流平均速度(厘米/秒)和门静脉血流量(毫升/分钟)。此外,还测量了肠系膜上动脉、肝动脉、脾内动脉和肾内动脉的搏动指数[(最大值 - 最小值)/平均速度]。22例患者口服纳多洛尔(80毫克)后120至180分钟再次测量这些参数,9例患者口服5 - 单硝酸异山梨酯(20毫克)后90分钟再次测量,随后对22例早期用纳多洛尔治疗的患者中的10例给予5 - 单硝酸异山梨酯后再次测量。7例患者服用安慰剂120分钟后也对双功多普勒超声参数进行了评估。在22例急性用纳多洛尔治疗的患者中,有5例在60分钟后未再给予任何药物的情况下再次测量相同参数。服用安慰剂后未出现血流动力学变化。纳多洛尔和5 - 单硝酸异山梨酯后门静脉血流平均速度和门静脉血流量降低;纳多洛尔和5 - 单硝酸异山梨酯后肠系膜搏动指数均升高。联合治疗后,我们观察到门静脉血流平均速度和门静脉血流量进一步降低,肝、脾和肠系膜搏动指数显著升高。纳多洛尔加用5 - 单硝酸异山梨酯使所有患者的门静脉血流平均速度降低超过17%。纳多洛尔使肾搏动指数略有升高,加用5 - 单硝酸异山梨酯后进一步升高,提示肾血流量减少。